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Genetic variability in response to amyloid beta
deposition influences Alzheimer’s disease risk
Dervis A. Salih,1,2 Sevinc Bayram,3 Sebastian Guelfi,4 Regina H. Reynolds,4
Maryam Shoai,2,4 Mina Ryten,4 Jonathan W. Brenton,1 David Zhang,4 Mar Matarin,4
Juan A. Botia,4,5 Runil Shah,4 Keeley J. Brookes,6 Tamar Guetta-Baranes,6 Kevin Morgan,6
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Genome-wide association studies of late-onset Alzheimer’s disease risk have previously identiﬁed genes primarily expressed in
microglia that form a transcriptional network. Using transgenic mouse models of amyloid deposition, we previously showed that
many of the mouse orthologues of these risk genes are co-expressed and associated with amyloid pathology. In this new study, we
generate an improved RNA-seq-derived network that is expressed in amyloid-responsive mouse microglia and we statistically com-
pare this with gene-level variation in previous human Alzheimer’s disease genome-wide association studies to predict at least four
new risk genes for the disease (OAS1, LAPTM5, ITGAM/CD11b and LILRB4). Of the mouse orthologues of these genes Oas1a is
likely to respond directly to amyloid at the transcriptional level, similarly to established risk gene Trem2, because the increase in
Oas1a and Trem2 transcripts in response to amyloid deposition in transgenic mice is signiﬁcantly higher than both the increase of
the average microglial transcript and the increase in microglial number. In contrast, the mouse orthologues of LAPTM5, ITGAM/
CD11b and LILRB4 (Laptm5, Itgam/CD11b and Lilra5) show increased transcripts in the presence of amyloid plaques similar in
magnitude to the increase of the average microglial transcript and the increase in microglia number, except that Laptm5 and
Lilra5 transcripts increase signiﬁcantly quicker than the average microglial transcript as the plaque load becomes dense. This work
suggests that genetic variability in the microglial response to amyloid deposition is a major determinant for Alzheimer’s disease
risk, and identiﬁcation of these genes may help to predict the risk of developing Alzheimer’s disease. These ﬁndings also provide
further insights into the mechanisms underlying Alzheimer’s disease for potential drug discovery.
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Introduction
All the known mutations in genes causing early-onset
Alzheimer’s disease alter amyloid precursor protein (APP)
processing such that amyloid deposition becomes more
likely (Hardy and Selkoe, 2002). In contrast, despite
some rare variants in APP processing enzymes (Kim
et al., 2009; Marioni et al., 2018; Jansen et al., 2019;
Kunkle et al., 2019), the majority of the risk in late-onset
disease has been shown to be due to sequence variability
in genes expressed in the innate immune system (largely
microglial genes; Jones et al., 2010). We and others iden-
tified the microglial gene TREM2 as a potent risk gene
for late-onset disease (Guerreiro et al., 2013; Jonsson
et al., 2013), and identified that its expression was
strongly increased by amyloid deposition in APP trans-
genic mice (Guerreiro et al., 2013; Matarin et al., 2015;
Cheng-Hathaway et al., 2018; Song et al., 2018). We
previously reported a microarray analysis of genome-wide
expression of a range of transgenic mice expressing mu-
tant human APP and/or PSEN1 (Matarin et al., 2015).
The different lines of mice analysed in this study devel-
oped amyloid plaques at different rates and so, by ana-
lysis of plaque deposition and gene expression in the
same animals, plaque deposition could be correlated with
gene expression across the life of a mouse, independent
of age. We noted that Trem2 was one of the genes
whose expression was up-regulated the most in relation
to amyloid deposition. Trem2 expression also showed a
strong correlation with the expression of a network of
genes in the innate immune system suggesting Trem2 is a
‘hub’ gene, and may regulate the expression of the entire
network. This immune module of genes showed a re-
markable positive correlation to amyloid deposition
(Matarin et al., 2015), and contained orthologues of
other already established Alzheimer’s disease risk genes
such as Abca7 and Ms4a6d (Lambert et al., 2013).
Notably, two genes, ABI3 and PLCG2, that were identi-
fied subsequently as being associated with Alzheimer’s
disease risk loci (Sims et al., 2017), were also present in
this network. Hence, mouse microglia clearly respond to
plaques in a manner where the genes co-expressed within
these microglia relate closely to the genes that are rele-
vant in human disease. These observations also suggest
that this innate immune network that is expressed by
these amyloid-responsive microglia may be used to pre-
dict future risk genes for Alzheimer’s disease.
An important outstanding question is whether progres-
sion of late-onset Alzheimer’s disease to the point of neu-
rodegeneration and diagnosis is largely due to an
inadequate innate immune response to rising amyloid beta
(Ab) deposition, resulting in accelerated amyloid-induced
damage (Edwards, 2019). This hypothesis is difficult to
study in human post-mortem tissue because during patho-
genesis the proportion of cell types in the brain changes
and the remaining cells show extensive compensatory
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changes in gene expression. With this in mind, for this
new work we developed the approach outlined below to
use the gene expression network that is present within
amyloid-responsive microglia in mouse models during
pathology progression, and tested for significant overlap
with human gene variation associated with Alzheimer’s
disease. We then surveyed the gene expression network in
mouse amyloid-responsive microglia to investigate if we
could identify further Alzheimer’s disease risk loci.
Initially, we took advantage of the increased resolution
provided by performing RNA-seq to improve the gene ex-
pression analysis we had previously undertaken with
microarray technology in the same mice. The new higher-
resolution transcriptional network containing the co-
expressed mRNA that most strongly correlated to amyloid
deposition again featured primarily microglial genes. This
confirmed the previous analysis in the same mice
(Matarin et al., 2015), but the mouse RNA-seq analysis
revealed many additional genes not detectable with micro-
array, and included yet more genes previously identified
as human risk genes for Alzheimer’s disease from gen-
ome-wide association studies (GWAS). We then investi-
gated whether the genes included in the novel co-
expression network present in amyloid-responsive mouse
microglia are also significantly associated with Alzheimer’s
disease in human GWAS data. We used the data from the
International Genomics of Alzheimer’s Projects (IGAP;
Lambert et al., 2013; Kunkle et al., 2019) to identify the
genes which are present in the mouse network and also
significantly associated with Alzheimer’s disease risk. The
significance of each human gene was assessed using a
gene-based approach, applied to the summary statistics of
the IGAP datasets (Brown, 1975; Moskvina et al., 2011;
Escott-Price et al., 2014; de Leeuw et al., 2015). The
gene-based analyses employed here account for the
strength of the association of multiple adjacent single nu-
cleotide polymorphisms (SNPs), restricted to the exon
boundaries of genes. This approach has important impli-
cations for predicting disease risk in people at the gene
level (rather than SNP-level), with the potential of provid-
ing mechanistic insights into the cellular and molecular
processes underlying disease progression.
Materials and methods
Mouse models of Alzheimer’s
disease
The RNA samples used for this study were from the
same mice we used previously, described in detail in
Matarin et al. (2015), therefore no further mice were
bred for this study. The mouse lines used are stated in
the Supplementary material. The mice procedures used
for Matarin et al. (2015), were performed in agreement
with the UK Animals (Scientific Procedures) Act, 1986,
with local ethical agreement.
Human genome-wide association
studies data
The original IGAP (Lambert et al., 2013) summary statistics
calculated for each SNP with 17008 Alzheimer’s disease
cases and 37154 controls (Stage 1) were used to derive the
gene-based P-values, described further below and in Escott-
Price et al. (2014). The updated IGAP (Kunkle et al., 2019)
summary statistics, derived from 21982 clinically confirmed
Alzheimer’s disease cases and 41944 controls (Stage 1)
were used to repeat the procedure and generate gene-based
P-values to determine if the associations identified from the
original IGAP data remained.
Mouse transcriptome work
For this study, RNA-seq library preparation and sequenc-
ing was performed by Eurofins Genomics (Ebersberg,
Germany), details given in Supplementary material to-
gether with processing of FASTQ files. Supplementary
Fig. 1 shows how the new RNA-seq data and new com-
parison to IGAP GWAS data for Alzheimer’s disease,
relates to total RNA samples collected previously in
Matarin et al. (2015).
Weighted gene co-expression network analyses were
performed as described in Matarin et al. (2015), using
the recommended parameters from the original analysis
developers (Zhang and Horvath, 2005; Horvath et al.,
2006; Oldham et al., 2006; Langfelder and Horvath,
2008). Further details are in Supplementary material.
Gene-based human genome-wide
association studies data analysis
The significance of the association to Alzheimer’s disease
of human genes was assessed using a gene-based ap-
proach as introduced in Brown (1975), Escott-Price et al.
(2014), and implemented in de Leeuw et al. (2015;
MAGMA software ctg.cncr.nl/software/magma). Briefly,
the updated IGAP (Kunkle et al., 2019) summary statis-
tics calculated for each SNP in a sample of 21 982
Alzheimer’s disease cases and 41 944 controls were used
to derive gene-based P-values. SNPs were assigned to
genes if they were located within the genomic sequence
corresponding to the start of the first and the end of the
last exon of each transcript. Previous analyses including
the 10 kb sequence flanking the first and last exons of
genes, which may contain potential regulatory SNPs, did
not cause substantial differences to the gene-based P-val-
ues (Escott-Price et al., 2014). Gene locations were as
Build 37, Assembly Hg19 of the National Center for
Biotechnology Information (NCBI) database as provided
as part of the MAGMA software package. Phase 3 of
1000 Genomes data were used as a reference panel for
calculation of linkage disequilibrium between markers
(Genomes Project Consortium et al., 2015). The gene-
wide analysis was performed based on the summary
Alzheimer’s risk genes in microglial network BRAIN COMMUNICATIONS 2019: Page 3 of 13 | 3
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/article-abstract/1/1/fcz022/5585002 by U
niversity C
ollege London user on 05 N
ovem
ber 2019
P-values while controlling for linkage disequilibrium and
different numbers of SNPs per gene using a statistical ap-
proach by Brown (1975), and adopted for set-based ana-
lysis of genetic data by Moskvina et al. (2011) and de
Leeuw et al. (2015). Prior to the gene-based analyses all
individual SNP P-values were corrected for the genomic
inflation factor (k; to normalise for unaccounted vari-
ation, due to factors such as population stratification;
Devlin and Roeder, 1999).
Statistical analysis comparing
human genes with co-expression
network of amyloid-responsive
mouse microglia
The lists of mouse genes in the co-expression networks
were converted to lists of human gene names using
convertMouseGeneList() function, library biomaRt in R
downloaded from https://bioconductor.org/biocLite.R. We
tested whether the number of Alzheimer’s disease associ-
ated genes (at significance thresholds alpha ¼ 0.05, 0.01
and 0.001) in the mouse co-expression network was
greater than that expected by chance given the number of
human orthologues present in the mouse network. For
that, we counted the observed number of independent
significant human genes in the mouse network and com-
pared this with the expected (by chance) number of genes
calculated as N*alpha, whilst accounting for the variance
(var¼N*alpha*(1-alpha)), where N was the total number
of independent human genes in the mouse network. To
account for linkage disequilibrium, the genes within
0.5Mb of each other were conservatively counted as one.
The P-value of the excess of significant genes in the
mouse network, between observed and expected, was cal-
culated using a Z-test comparing the number of observed
significant genes with the expected number. The observed
number of significant genes was significantly higher than
Figure 1 An innate immune network of genes expressed by amyloid-responsive microglia, featuring several orthologues of
established GWAS genes associated with Alzheimer’s disease, predicts the importance of four new risk genes that may
influence the risk of developing Alzheimer’s disease. Network plot using VisANTreveals key drivers of an innate immune module from
RNA-seq derived gene expression from the hippocampus of wild-type and amyloid mice. Red circles show orthologues of established GWAS
genes associated with Alzheimer’s disease including Trem2, Abi3, Cd33 and Spi1/PU.1. Blue underline shows gene orthologues predicted to confer
altered risk of Alzheimer’s disease by overlapping a gene co-expression network present in mouse microglia that show a strong response to
amyloid in transgenic mice with individual human genes significantly associated with Alzheimer’s disease by analysing combinations of adjacent
SNPs (see Materials and methods section; Escott-Price et al., 2014). Genes shown in this network are transcribed and co-expressed in amyloid-
responsive microglia. Larger red spheres represent ‘hub’ genes, those showing the greatest number of connections to other genes in the
network, and include Trem2, Tryobp, Lilrb4a, P2ry13, Ctss, Ctsz, Mpeg1 and Plek, which are likely to play important roles in driving microglial
function.
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the expected at all gene P-value thresholds (0.05, 0.01,
0.001) for the amyloid-associated network. We report the
genes at the gene-based P-values at threshold alpha ¼ 0.01.
Data availability statement
RNA-seq expression data have been deposited in NCBI’s
Gene Expression Omnibus (GEO; Series accession number
GSE137313; https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc¼GSE137313), and are available at: www.
mouseac.org.
Results
High-resolution co-expression
network using RNA-seq in amyloid-
responsive microglia
Although mouse models for dementia have clear limita-
tions in that they do not show tau tangles or neuronal
loss solely in response to rising Ab, they allow us to
study the time-course response of a healthy innate im-
mune system reacting to Ab, leading to the possibility
that the innate immune cells of the mouse may ultimately
be preventing Ab killing neurons. We previously con-
structed a transcriptional network using expression arrays
that was present in microglia that respond to plaques
(Matarin et al., 2015). As microarrays are limited by
their probe content and their dynamic range, for this new
study we have now sequenced the transcriptome of the
same mice, expressing one or two copies of the APP
(Swedish) and/or PSEN1 (M146V) transgenes alongside
wild-type controls, using RNA-seq to construct a new
higher resolution expression network. Similar to our find-
ings with the initial microarray analysis, the RNA-seq
analysis revealed a microglial module of genes that
showed a strong correlation with Ab deposition (correl-
ation ¼ 0.94; P< 3e41), and contained the mouse ortho-
logues of the identified GWAS loci TREM2, ABI3,
CD33, INPP5D, MS4A6D, SPI1/PU.1, PLCG2,
GAL3ST4, RIN3, HLA and APOE (Supplementary
Table 1), verifying the relevance of this gene network to
the human condition. Our hypothesis is that this network
contains most of the genes that the microglia need to re-
spond to amyloid plaques, including genes necessary for
increases in cell number and activation (thus many cellu-
lar responses including proliferation, survival, metabolism,
activation into a variety of states and phagocytosis). The
genes showing the tightest expression correlation within
the module associated with microglia reacting to plaques
form the network shown in Fig. 1 and Supplementary
Table 2 (top 147 genes from a total of 1584 genes
expressed as part of the innate immune module based on
the topological overlap measure, connectivity values).
This network is broadly similar to the network derived
from the analysis of the same RNA by microarray
methods (Matarin et al., 2015) and shows common fea-
tures with microglial networks published by other groups
using other amyloid mouse models (Wang et al., 2015;
Castillo et al., 2017; Keren-Shaul et al., 2017; Lee et al.,
2018; Nam et al., 2018), suggesting this is a conserved
core network of genes that can be reliably identified
using different methodologies. Trem2 forms a hub gene
in our network, using either technique, indicating that
Trem2 expression is highly correlated to many other
genes in the network, and may drive the response of this
network. In line with this idea, Trem2 has been shown
to regulate at least part of this immune module (Wang
et al., 2015; Keren-Shaul et al., 2017; Lee et al., 2018).
The network we identified is also broadly similar to a
human network of innate immune genes containing
TYROBP, TREM2, MS4A family genes, C1Q members
and CD33, identified from human post-mortem tissue
bearing in mind the caveats discussed above for human
tissue (Forabosco et al., 2013; Zhang et al., 2013). Again
this suggests that this gene network expressed by Ab-re-
sponsive mouse microglia behaves similarly in humans.
Enrichment of human Alzheimer’s
disease genes in the mouse gene
network expressed by amyloid-
responsive microglia
Traditionally, GWAS projects have focused on single
SNPs because single locus tests are the easiest to test and
interpret, but these have limitations. For example, if dis-
ease risk is conferred by several (semi) independent SNPs
within a locus with moderate effect sizes, this locus
(gene) will be overlooked by the genome-wide analyses,
as the statistical significance of each individual SNP will
not pass the Bonferroni correction. Therefore, if only sin-
gle SNPs are considered, useful disease associations may
be lost, despite apparently high sample sizes (Escott-Price
et al., 2014). To identify genes associated with
Alzheimer’s disease at the gene-based level we initially
used the summary statistics from the original IGAP
(Lambert et al., 2013), and then re-ran the gene-based
analyses using the larger updated IGAP data (Kunkle
et al., 2019). We considered multiple SNPs within indi-
vidual human genes to generate gene-level P-values in
order to assess whether multiple SNPs together constitute
a significant risk factor, using a gene-based approach
applied to the Alzheimer’s disease GWAS summary statis-
tics (Brown, 1975; Escott-Price et al., 2014; de Leeuw
et al., 2015). Within our mouse innate immune network,
we first confirmed the significance of several members of
the network that were orthologues of established
Alzheimer’s disease loci variants using the gene-level
P-values, including genes such as Trem2 and Abi3
(Table 1). We then asked whether the other members of
the mouse network expressed by amyloid-responsive
microglia might predict additional risk for Alzheimer’s
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disease. To this end, we identified orthologues of human
genes in the mouse network and tested whether this set
of genes is enriched for the genes which contain variants
significantly associated with Alzheimer’s disease. As this
set of genes was defined by our biological experiment in
contrast to genome-wide analyses, which by their nature
are exploratory rather than hypothesis driven, we consid-
ered a nominal statistical significance threshold of
P¼ 0.05 for human Alzheimer’s disease gene-based asso-
ciations. We also explored more stringent significance
thresholds (P¼ 0.01 and P¼ 0.001), for selection of the
genes for the gene enrichment analysis. To ensure that
our enrichment analysis results were not inflated by the
correlated genes due to linkage disequilibrium (i.e. in
close proximity to one another), the genes within 0.5 Mb
of each other were counted as one. We found a signifi-
cant enrichment of orthologues of human genes associ-
ated with Alzheimer’s disease at the P¼ 0.01 significance
threshold within this mouse network expressed by amyl-
oid-responsive microglia over and above that expected by
chance (P¼ 8.86 106). The enrichment remained sig-
nificant even after the established GWAS loci were
excluded [P¼ 1.66 104 for highly connected network
of 147 genes (Fig. 1) and similarly P¼ 3.68 104 for
the entire module of 1584 genes (Supplementary Table
1)]. GWAS loci boundaries were defined as 0.5Mb from
either side of the most significant SNPs of previously
identified GWAS genes with exclusion of APOE and
HLA which we defined as chromosome 19:
44 500 00046 500 000 and chromosome 6: 32 200 000 
32 800 000, respectively.
In contrast to the mouse gene network expressed by
amyloid-responsive microglia, the innate immune network
expressed by microglia responding to tau pathology in
mice transgenic for tau (P301L), was not significantly
enriched for human genes associated with Alzheimer’s
disease using the same methods (P¼ 0.78), although
Apoe is part of this module and this module also con-
tained genes largely expressed by microglia
(Supplementary Fig. 2, top 137 genes from a total of
2299 genes in the module based on the topological over-
lap measure). When the entire module of innate immune
genes expressed by tauopathy-responsive microglia (2299
genes) was considered there was a modest significant en-
richment, P¼ 1.74  102, suggesting that a proportion
of genes associated with Alzheimer’s disease through mul-
tiple SNPs are microglial genes that have mouse ortho-
logues, but are expressed by microglia that are less
responsive to tau pathology compared to Ab deposition.
The analysis of the genetic network expressed by amyl-
oid-responsive microglia identified five genes within the
central portion of mouse microglial network whose
human orthologues were associated with Alzheimer’s dis-
ease from the original IGAP data [described in Salih
et al. (2018), using the IGAP data from Lambert et al.
(2013)]. When we repeated the analysis using the
updated IGAP data (Kunkle et al., 2019) containing
29.2% more cases and 12.9% more controls, and 62.7%
more SNPs as compared to Lambert et al. (2013), four
of the five identified genes from the centre of the co-ex-
pression network in mice were still strongly associated
with the orthologues containing variants in human
Alzheimer’s disease. These four genes, OAS1, LAPTM5,
ITGAM/CD11b and LILRB4, have not been previously
reported as having variants significantly associated with
Alzheimer’s disease using traditional GWAS approaches
Table 1 The genes predicted to contain variants associated with Alzheimer’s disease together with established loci
from GWAS
Mouse
symbol
(MGI)
Human
symbol
(HGNC)
NCBI
ID
Human
chromo-
some
Start
location
End location Number
of SNPs
Gene P-value
(adj for GC)
Best SNP Best SNP
Location
Best SNP
p-value
Effect
size
Risk
Allele
Frequency
Predicted genes
Laptm5 LAPTM5 7805 1 31205316 31230667 71 6.62E05 rs7549164 31224193 4.15E04 0.0655 T 0.1935
Oas1a OAS1 4938 12 113344582 113371027 126 1.58E03 rs4766676 113365581 6.16E04 0.0518 T 0.6209
Itgam ITGAM 3684 16 31271288 31344213 168 4.92E03 rs79113991 31273662 4.48E03 0.0656 A 0.1308
Lilra5 LILRB4 11006 19 55155340 55181810 148 8.96E03 rs731170 55176262 1.72E03 0.0513 A 0.3023
Established GWAS genes
Inpp5d INPP5D 3635 2 233924677 234116549 720 9.81E06 rs10933431 233981912 2.55E07 0.1001 C 0.7774
Trem2 TREM2 54209 6 41126244 41130924 5 1.47E08 rs7748513 41127972 1.81E03 0.1175 A 0.9617
Gal3st4 GAL3ST4 79690 7 99756867 99766373 21 4.68E03 rs34130487 99759205 3.47E03 0.0474 T 0.2811
Spi1 SPI1 6688 11 47376411 47400127 87 8.96E12 rs3740688 47380340 9.70E11 0.0935 T 0.5524
Ms4a6d MS4A6A 64231 11 59939487 59952139 33 2.10E12 rs7935829 59942815 6.78E15 0.1134 A 0.5979
Abi3 ABI3 51225 17 47287589 47300587 47 4.93E02 rs9896800 47293329 8.62E03 0.0417 T 0.6772
Cd33 CD33 945 19 51728320 51747115 34 1.09E06 rs12459419 51728477 4.51E07 0.0800 T 0.3076
Genes predicted to confer altered risk of Alzheimer’s disease by overlapping gene expression data transcribed by microglia that show a strong response to plaques in amyloid mice
(Fig. 1) with individual human genes significantly associated with Alzheimer’s disease by analysing combinations of adjacent SNPs (see Materials and methods section; Escott-Price
et al., 2014). The SNP data were from the updated IGAP study, using Build 37, Assembly Hg19 (Kunkle et al., 2019). The SNP with the most significant p-value within each gene is
denoted as ‘Best SNP,’ and is stated for completion from the updated IGAP stage 1 dataset, but was not used for any statistical calculations in this manuscript. The effect size (coeffi-
cient of the logistic regression) is provided for the best reported SNP from IGAP data; a positive number indicates that the allele increases risk of Alzheimer’s disease, and so a nega-
tive number indicates the allele is protective. The allele frequency from the IGAP study is also provided. The established genes altering risk for Alzheimer’s disease from GWAS are
given for comparison.
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(Table 1, Supplementary Figs 3 and 4). In addition,
amongst the entire genetic network expressed by amyl-
oid-responsive microglia (Supplementary Table 1; 1584
genes), a further 12 mouse genes have orthologues associ-
ated with human Alzheimer’s disease (P< 0.01) from the
updated IGAP study (Supplementary Table 3). We em-
phasise that the goal of this comparison between the gen-
etic network in mouse amyloid-responsive microglia
versus human genes associated with Alzheimer’s disease
combining multiple SNPs in a given gene was not to
identify new single SNPs with genome-wide significant
P-values 5  108. Instead, the alternative approaches
we describe here were used to survey for more complex
relationships between DNA variation and coding genes
associated with Alzheimer’s disease by: (1) selecting a net-
work of biologically relevant genes to Alzheimer’s disease
genes (which reduces dramatically the number of genes
being surveyed, to 1584 genes in our amyloid-associated
network); (2) considering all SNPs together bounded by
the coding region of a given gene (the gene-based ana-
lysis); and (3) looking at the network as a whole rather
than individual genes (the enrichment analysis). Hence
the individual gene significance is modest as compared to
the genome-wide levels, but the genes are statistically sig-
nificant and, together with previously identified
Alzheimer’s disease genes, form the core of a transcrip-
tional gene network (Fig. 1 and Table 1).
If we consider a sub-network of genes expressed by
amyloid-responsive microglia that contains these four
novel putative risk genes with the established GWAS loci
TREM2, ABI3, CD33, INPP5D, SPI1/PU.1, MS4A6D
and GAL3ST4 present in Fig. 1, this sub-network is not
highly connected in an innate immune gene network
associated with tauopathy (Supplementary Fig. 2), sug-
gesting this sub-network is expressed by microglia that
are more responsive to amyloid deposition than other
pathological features. Furthermore, in common with the
existing seven known GWAS-associated genes in Fig. 1,
the four novel risk genes we identify that are expressed
by microglia that respond to Ab deposition show tran-
script levels rising from 4 months of age in the homozy-
gous APP/PSEN1 mice and after 4 months of age in the
hemizygous APP/PSEN1 mice (Supplementary Fig. 5), in
line with the increase in microglial numbers as amyloid
plaques begin to deposit (Medawar et al., 2019). To in-
vestigate whether the transcriptional changes we observed
here are due to the increased microglial numbers in re-
sponse to amyloid plaques we observed previously
(Medawar et al., 2019), and to determine which genes
are directly up-regulated or down-regulated by amyloid
at the mRNA level beyond the changes in microglial
number, we calculated fold change of each gene in the
homozygous and hemizygous APP/PSEN1 mice relative
to its expression in age-matched wild-type mice
(Supplementary Fig. 6). The expression levels of our puta-
tive risk genes relative to expression in age-matched wild-
type mice shows a range (Oas1a, 10.0-fold increase in
homozygous APP/PSEN1 mice relative to wild-type at
18months of age; Laptm5, 4.1-fold increase; Lilra5, 3.8-
fold increase; Itgam/CD11b, 2.3-fold increase; compared
to Trem2, 9.2-fold increase, and Aif1, 3.3-fold increase;
Supplementary Fig. 6). Genes showing higher relative
transcript levels such as Oas1a and Trem2 compared to
the average transcript level relative to wild-type mice for
the entire innate immune network throughout disease
progression, thus are likely to be directly up-regulated in
response to amyloid by the reacting microglia, consider-
ing the number of microglia (3.7-fold increase in micro-
glia at 18months of age in homozygous APP/PSEN1
mice compared to wild-type; Medawar et al., 2019). In
contrast, Laptm5 and Lilra5 relative expression are only
significantly increased relative to average transcript level
of the entire network when the plaque load starts to be-
come heavy (8months of age), but returns to the average
relative transcript level of the network as disease pro-
gresses, suggesting a role in the initial response to Ab
(Supplementary Fig. 6). Itgam/CD11b shows a similar
change in relative expression to the average relative tran-
script level of the entire immune network, and to the in-
crease in microglia numbers, comparable to relative Spi1/
PU.1 expression, suggesting that Itgam/CD11b and Spi1/
PU.1 transcription is unlikely to be directly regulated by
Ab, but may play a role in regulating the change in
microglia number in response to amyloid plaques because
of the strong correlation between pathology and Itgam/
CD11b expression. The expression patterns for Oas1a,
Lilra5 and Itgam/CD11b are similar in both the homozy-
gous and hemizygous APP/PSEN1 mice (Supplementary
Fig. 6), whereas Laptm5 shows an expression pattern in
the hemizygous APP/PSEN1 mice that is more similar to
Itgam/CD11b. The similarity of the expression profiles of
Laptm5, Itgam/CD11b and Spi1/PU.1 in the hemizygous
APP/PSEN1 mice suggests that these three genes may
play a role in regulating microglial number in response
to amyloid deposition.
Transcriptional network expressed
by amyloid-responsive microglia
containing risk genes is conserved
in humans
Aspects of the transcriptional network associated with
amyloid that we identified in our analysis, containing the
four predicted risk genes with the existing seven GWAS
loci, are broadly similar to microglial networks we and
others have previously identified in human brain analyses.
Zhang et al. identified an Alzheimer’s disease-relevant
network centred on TYROBP and TREM2, which con-
tained ITGAM/CD11b and LAPTM5 (Zhang et al.,
2013), and we described a human microglial network
containing LAPTM5, ITGAM/CD11b and LILRB4
(Forabosco et al., 2013). We then determined whether
these novel Alzheimer’s disease risk genes, derived from a
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mouse transcriptional network expressed by amyloid-re-
sponsive microglia were present in independent datasets
of human brain co-expression networks. Cross referenc-
ing our network with the data from the ROS/MAP pro-
ject (Bennett et al., 2012a, b; De Jager et al., 2018),
revealed that LAPTM5, ITGAM/CD11b and LILRB4
clustered together with many of the GWAS risk genes for
Alzheimer’s disease (Supplementary Fig. 7; Fisher’s Exact
test Bonferroni corrected P¼ 1.34  1013 showing a sig-
nificant overlap between the genes in the mouse amyloid-
associated module and human genes in the ROS/MAP
module associated with Alzheimer’s disease). Interestingly,
SPI1/PU.1, the myeloid cell transcription factor and a
newly discovered GWAS risk gene (Huang et al., 2017)
was also in the same ROS/MAP module as LAPTM5,
ITGAM/CD11b and LILRB4. We confirmed these mod-
ule memberships in the BRAINEAC data for non-
Alzheimer’s disease control human brains generated in
our own lab (Ramasamy et al., 2014). Interestingly, we
found that SPI1/PU.1 binds to the regulatory regions of
Laptm5 and Itgam/CD11b, as well as established
Alzheimer’s disease risk gene orthologues Trem2, Abi3,
Inpp5d, Ms4a6d and Spi1/PU.1 itself, by searching data
from a chromatin immunoprecipitation experiment
against SPI1/PU.1 in mouse microglial-like BV-2 cells
(Satoh et al., 2014). This finding was supported by min-
ing for regulatory features and cis-regulatory modules in
the gene network expressed by microglia that respond to
plaques using i-cisTarget that uses a library of regulatory
data (Imrichova et al., 2015). Together, these findings
suggest that several of the predicted and established
Alzheimer’s disease risk genes may be regulated by SPI1/
PU.1, which itself alters Alzheimer’s disease risk by coor-
dinating a program of microglial-expressed genes (Huang
et al., 2017).
Colocalization between Alzheimer’s
disease-related loci and expression
quantitative trait loci for gene OAS1
Since most GWAS loci are thought to operate by regulat-
ing the expression of neighbouring genes (Bradshaw
et al., 2013; Griciuc et al., 2013; Huang et al., 2017),
for each of the four potential Alzheimer’s disease-associ-
ated genes we performed a colocalization analysis to test
the association between Alzheimer’s disease-related loci
located within these genes and loci regulating the expres-
sion of these genes (eQTLs) (Giambartolomei et al.,
2014). eQTLs were obtained from two previously
published datasets using baseline and stimulated human-
derived monocytes and iPSC-derived macrophages (Kim-
Hellmuth et al., 2017; Alasoo et al., 2018). In these
studies, macrophages and monocytes were stimulated
with various immunostimulants to activate distinct, well-
characterised immune signalling pathways, including
those broadly associated with bacterial and viral
responses. Interestingly, we identified three colocalizations
between Alzheimer’s disease loci and eQTLs regulating
OAS1 gene expression, all of which were identified in
stimulated states, suggesting that this association is only
active in certain environmental conditions (Fig. 2 and
Supplementary Figs 8 and 9), in particular those designed
to model monocyte/macrophage priming or more chronic
inflammation.
Discussion
A decade of GWAS projects for Alzheimer’s disease has
provided key and initially surprising insights into the pro-
gression of late-onset Alzheimer’s disease, particularly the
dependence on the innate immune system, with the iden-
tification of genes such as TREM2 and SPI1/PU.1
(Guerreiro et al., 2013; Jonsson et al., 2013; Huang
et al., 2017; Sims et al., 2017). The latest GWAS studies
published during 2019 mark the largest of their kind for
Alzheimer’s disease featuring 71 880 Alzheimer’s disease
cases to identify 9 novel risk loci (Jansen et al., 2019),
and 35 274 clinically assessed Alzheimer’s disease cases to
identify 5 novel risk loci from the updated IGAP study
(Kunkle et al., 2019). Despite all the risk genes that have
been discovered by GWAS, they still do not account for
all of the heritability of late-onset Alzheimer’s disease.
Finding further risk genes will become increasingly diffi-
cult due to the sheer number of patients required and
associated costs, as the remaining risk genes are likely to
be of rare mutation frequency or lower effect size. Here,
we describe a new approach to identify further risk genes
by intersecting transcriptome data from a functional cel-
lular response to rising amyloid with a gene-based statis-
tical approach to identify genes significantly associated
with Alzheimer’s disease from the updated IGAP project.
We identify four further potential risk genes, OAS1,
LAPTM5, ITGAM/CD11b and LILRB4, alongside con-
firming the importance of seven established GWAS hits
TREM2, ABI3, CD33, INPP5D, SPI1/PU.1, MS4A6D
and GAL3ST4. Together these new and established genes
form a transcriptional network that is conserved in mice
and humans, and so suggests that this sub-network of
genes are regulated together, in part by the SPI1/PU.1
transcription factor, and may function together.
Surveying the literature on our genes of interest
revealed that OAS1 (2-prime, 5-prime oligoadenylate syn-
thetase 1) is involved in the regulation of cytokine ex-
pression (Lee et al., 2019). OAS1 is induced by
interferons (Donovan et al., 2013), which supports our
eQTL analysis showing that one of the best SNPs we
identified for OAS1 appears in a locus which acts as an
eQTL in response to interferon-c (IFNc; Fig. 2 and
Supplementary Figs 8 and 9). OAS1 can additionally acti-
vate ribonuclease L, which degrades viral RNA and
inhibits viral replication (Donovan et al., 2013).
Interferons are cytokines that are thought to trigger a key
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response to viral and other pathogens. In addition to the
mouse orthologue of OAS1 (Oas1a), a number of other
genes involved in interferon signalling are also present in
our co-expression network from amyloid-responsive
microglia, including other Oas family members, Ifit mem-
bers, and transcription factors such as Irf7, Trp53 and
the Stat family (Supplementary Tables 1 and 2). Recent
studies have also shown that interferon-related genes are
expressed in ageing control mice, and that the expression
of interferon-related genes is further elevated in mouse
models with amyloid pathology (Friedman et al., 2018;
Sala Frigerio et al., 2019), leading to the identification of
a population of ‘interferon response microglia’ (Sala
Frigerio et al., 2019). The role of OAS1 and the other
interferon-related genes in ageing animals and Alzheimer’s
disease is not clear, they may be involved in limiting viral
infections, recruiting immune cells to sites of damage
and/or regulating cytokine production.
LAPTM5 (lysosome-associated protein, transmembrane
5) is associated with amyloid deposition in transgenic
mice (Nam et al., 2018). LILRB4 (leukocyte immuno-
globulin-like receptor, subfamily B, member 4), ortho-
logues have also been shown to be increased with
amyloid deposition and specifically associated with amyl-
oid plaques (Wirz et al., 2013; Kamphuis et al., 2016;
Castillo et al., 2017). A paralogue of LILRB4, named
LILRB2, and its mouse orthologue Pirb have been
shown to bind Ab, and this interaction with Ab in mice
mediates synapse elimination, and deficits in synaptic
plasticity and memory (Kim et al., 2013). The functions
of LAPTM5 and LILRB4 have not been well character-
ised, but are thought to suppress the activation of a var-
iety of immune cells. ITGAM/CD11b (or CR3A), is a cell
surface receptor involved in activation, migration and
phagocytosis of immune cells, so much so that ITGAM/
CD11b is used as a marker of activated microglia
(Matsuoka et al., 2001; Heneka et al., 2013; Kamphuis
et al., 2016). ITGAM/CD11b was highlighted in recent
genetic and functional analyses as likely being important
for the progression of Alzheimer’s disease, whose expres-
sion was driven by SPI1/PU.1, and related to amyloid de-
position in mice and humans (Zhang et al., 2013; Hong
et al., 2016; Kamphuis et al., 2016; Olmos-Alonso et al.,
2016; Huang et al., 2017; Nam et al., 2018). Most re-
cently, inhibiting the interaction between the blood pro-
tein fibrinogen and ITGAM/CD11b reduced synaptic
elimination and cognitive decline in a mouse model of
Alzheimer’s disease (Merlini et al., 2019), providing
strong evidence that ITGAM/CD11b function contributes
to disease development. Given the previous studies for
ITGAM/CD11b, LAPTM5 and LILRB4, it is tempting to
speculate that they are involved in phagocytic processes
involving synapses which are known to be reactivated
during Alzheimer’s disease progression. More work is
Figure 2 Colocalization of Alzheimer’s disease GWAS loci with eQTLs derived from baseline and stimulated iPSC-derived
macrophages. Colocalization of Alzheimer’s disease loci and eQTLs targeting OAS1 in baseline and stimulated states (interferon-c and
Salmonella, 18 and 5 h, respectively). In the eQTL panels, grey and red data points represent macrophages at baseline or stimulated with both
interferon-c and Salmonella, respectively. The eQTL data are from Alasoo et al. (2018). The best Alzheimer’s disease locus in OAS1 from the
IGAP data (Lambert et al., 2013) is highlighted with the black line. Numerical results are reported in Supplementary Table 4.
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necessary to understand the molecular mechanisms of all
four of these putative risk genes in the progression of
Alzheimer’s disease.
It is also useful to consider how microglial prolifer-
ation in response to amyloid plaques relates to expres-
sion of the four putative risk genes. We have previously
shown that microglial number is increased in these
homozygous APP/PSEN1 mice, by around 3.7-fold in
the CA1 region of the hippocampus (Medawar et al.,
2019), and an elegant study by Srinivasan et al. (2016),
delineates the difference between expression changes in
bulk tissue versus the influence of increased microglial
numbers in response to amyloid by cell sorting to ana-
lyse expression changes in purified microglia alone. The
expression levels of our putative risk genes relative to ex-
pression in age-matched wild-type mice shows a range,
with Oas1a showing the greatest relative expression
(10.0-fold increase relative to wild-type), and Itgam/
CD11b showing the lowest relative expression (2.3-fold
increase), suggesting that these genes may fulfil different
purposes in microglia in the presence of amyloid plaques.
Genes showing higher relative transcript levels such as
Oas1a and Trem2 are likely to be directly up-regulated
by microglia in response to amyloid, and may be pro-
moting a protective response to amyloid e.g. as described
by Lee et al. (2018). Oas1a shows increased expression
in purified microglia from a number of different mouse
models of Alzheimer’s disease, using the Myeloid
Landscape datasets suggesting Oas1a is directly up-regu-
lated by amyloid (http://research-pub.gene.com/
BrainMyeloidLandscape/#; Friedman et al., 2018).
Laptm5 and Lilra5 relative expression are only signifi-
cantly increased in homozygous APP/PSEN1 mice when
the plaque load starts to become heavy (8months of
age), suggesting direct regulation by amyloid only as the
plaque load increases, implying a specific role for these
genes in microglia at this stage. Instead, Itgam/CD11b
shows a similar change in relative expression to the aver-
age relative transcript level of the entire immune net-
work, and to the increase in microglia number,
comparable to relative Spi1/PU.1 expression. This sug-
gests that Itgam/CD11b and Spi1/PU.1 genes may play a
role in regulating the change in microglia number in re-
sponse to amyloid plaques, given the strong correlation
between the expression of these genes and amyloid
pathology.
The study by Huang et al. (2017) shows that a com-
mon SNP in the population delays onset of Alzheimer’s
disease, purportedly via reduced expression of SPI1/PU.1.
However, in our study we see a positive correlation be-
tween Spi1/PU.1 and candidate genes Laptm5 and Itgam/
CD11b, as well as established risk genes Trem2 and
Abi3, which all have binding sites in their promoters for
SPI1/PU.1, suggesting that SPI1/PU.1 is a positive regula-
tor of these genes in this mouse model where heavy
amyloid load does not lead to tangles and neurodegenera-
tion. This discrepancy may be due to differences in the
increase in microglial number between mice and humans;
our data suggest that Spi1/PU.1 may be regulating micro-
glial number, and it is possible that the level of microglial
proliferation that can be tolerated by mice and humans
is different (particularly given the long course of
Alzheimer’s disease in humans). Not all Alzheimer’s dis-
ease risk genes have SPI1/PU.1 binding sites; thus, while
this core transcription factor plays a substantial role in
the progression of disease, there are likely to be auxiliary,
environment-dependent transcription factors that modify
disease development. In future work, it would be good to
complement the bulk RNA-seq analysis here with isolated
microglia and single-cell work for microglia to determine
how Spi1/PU.1 expression and the transcriptome is differ-
ent for microglia proximal to plaques versus those away
from plaques, and in different regions of the brain. In
studies where microglia are isolated, the limitations asso-
ciated with purifying microglia should be borne in mind,
in that the procedure may alter some transcripts, and it
is also important to consider the heterogeneity of micro-
glia seen from single-cell work (Sala Frigerio et al.,
2019). Further work is required to understand how the
putative risk genes respond to amyloid within microglia,
both at the transcriptional level, and at the post-transla-
tional level. Notably, while there is evidence that these
putative risk genes have been coincidentally linked with
amyloid plaques, there is no published evidence to date
that DNA variation in these genes in the human popula-
tion is linked to risk for Alzheimer’s disease.
Our data also show that microglia respond differently
to amyloid deposition versus tauopathy, with around
29% of transcripts in amyloid-responsive microglia show-
ing a stronger correlation to amyloid pathology. A recent
study also presents related data, identifying a co-expres-
sion module within microglia that respond more robustly
to amyloid pathology compared to tauopathy (Sierksma
et al., 2019). In both studies, established and putative
Alzheimer’s disease risk genes are more strongly enriched
in the amyloid-responsive microglia compared to tauop-
athy-responsive microglia. These data collectively provide
compelling evidence that the microglial response to amyl-
oid pathology determines whether the disease progresses
to neurodegeneration and cognitive problems. Further
work is required to understand how the microglial re-
sponse to tauopathy is different, and why mouse models
with heavy amyloid plaque loads do not lead to tau tan-
gles and neurodegeneration. It may be that other triggers,
in addition to amyloid deposition, are required to push
microglia to a state that permits amyloid-dependent tau
pathology, such as blood–brain barrier breakdown or pri-
ming of the immune system by exposure to environmen-
tal pathogens. Alternatively, it may be due to microglial
genes expressed more abundantly in human microglia
compared to mouse.
This work focuses on the commonality between mice
and humans, specifically how expression of mouse micro-
glial genes overlap with human genes showing DNA
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variation associated with Alzheimer’s disease. It is worth-
while to bear in mind that a number of important studies
have compared gene expression in microglia from mice
and humans, and while they have shown a significant over-
lap between the transcriptomes of the two species, they
have also seen a number of genes are expressed selectively
more abundantly in human microglia (Miller et al., 2010;
Galatro et al., 2017; Gosselin et al., 2017). Our four puta-
tive risk genes, OAS1, LAPTM5, LILRB4 and ITGAM/
CD11b are expressed abundantly in the human microglia
(Galatro et al., 2017; Gosselin et al., 2017), and more gen-
erally there is a substantial overlap in human orthologues
expressed by the mouse amyloid-responsive microglia and
the transcripts expressed abundantly by human microglia
from Galatro et al. (2017) and Gosselin et al. (2017).
Genes expressed more abundantly in human microglia and
not present in our mouse microglial network are given in
Supplementary Table 5. Thus, in future studies it is import-
ant to select the appropriate model for the study of specific
microglia genes.
The importance of this work is 2-fold. First, by identi-
fying more genetic loci involved in amyloid deposition,
we derive a more complete insight into the cellular proc-
esses and molecular mechanisms underlying the disease.
In this regard, this work is complementary to that of
Huang et al. (2017), showing that microglial SPI1/PU.1-
driven transcription is a common feature of many
Alzheimer’s disease loci. These findings are also consistent
with previous work on Trem2 (Wang et al., 2015;
Keren-Shaul et al., 2017; Mazaheri et al., 2017; Cheng-
Hathaway et al., 2018; Lee et al., 2018), and CD33
(Bradshaw et al., 2013; Griciuc et al., 2013), suggesting
these risk genes are crucial in controlling the microglial
response to amyloid-induced damage. Understanding the
mechanisms of function of TREM2 and the sub-network
of genes expressed by amyloid-responsive microglia iden-
tified here may be useful to leverage therapeutic opportu-
nities. Second, and perhaps of greater importance, this
work implies that, overall, how well an individual
responds to amyloid deposition at the cellular and gene
expression level plays a part in determining one’s risk of
disease, and understanding the genes that control this
may be used to predict the chances of developing
Alzheimer’s disease and to develop preventative or dis-
ease-delaying treatments before irreversible neurodegener-
ation sets in.
Supplementary material
Supplementary material is available at Brain
Communications online.
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